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Abstract
Objective: To evaluate the short-term efficacy of intravitreal bevacizumab (IVB) and posterior
sub-tenon triamcinolone injections (PSTI) on the basis of spectral-domain optical coherence
tomography (SD-OCT) patterns in diabetic macular edema (DME).
Methods:We retrospectively reviewed 73 eyes of 73 patients with DME. Based on the presence
of serous retinal detachment (SRD), eyes were categorized into two groups, and either IVB or
PSTI treatment was performed. Central macular thickness (CMT) and the degree of SRD were
assessed preoperatively and 1 month postoperatively. The severity of intraretinal edema was
approximated based on the distance from the external limiting membrane to the internal limit-
ing membrane.
Results: In eyes with SRD, reduction of SRD was greater with IVB than with PSTI. Moreover,
reduction of intraretinal edema was greater with PSTI than with IVB. In eyes without SRD, PSTI
achieved greater CMT reduction, compared with IVB.
Conclusions: In DME patients with SRD, IVB achieved greater reduction of SRD, compared with
PSTI; however, intraretinal edema responded more favorably to PSTI, regardless of the presence
of SRD. Our results suggest that the classification of DME based on OCT findings may be useful
to predict responses to IVB or PSTI treatments.
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Introduction
Diabetic macular edema (DME) is a leading
cause of visual impairment in patients with
diabetic retinopathy. Although the precise
pathophysiology of DME remains unclear,1
vascular endothelial growth factor (VEGF)
plays an important role in increasing vascu-
lar permeability in diabetic retinopathy;2
moreover, the roles of many inflammatory
cytokines have been reported in association
with development of DME.3–5 Grid/focal
laser treatment, or the use of corticosteroid
via intravitreal route or posterior sub-tenon
space, constitute the conventional treat-
ment modalities for DME. Recently, the
use of anti-VEGF agents has provided
effective treatment of DME, such that
anti-VEGF therapy has become a
common treatment modality for DME.6
The morphology of DME can be classi-
fied into cystoid macular edema, sponge-like
diffuse retinal swelling, and serous retinal
detachment (SRD).7 However, DME often
presents as combinations of multiple types,
such that clear classification is difficult in
some cases. Furthermore, little information
is available with regard to pretreatment opti-
cal coherence tomography (OCT) patterns
of DME and patterns associated with differ-
ent treatments. In some patients, DME per-
sists after repeated intravitreal bevacizumab
injection (IVB), but may respond favorably
to intravitreal triamcinolone acetonide
injection (IVTA).8 Likewise, refractory
DME, unresponsive to IVTA, reportedly
improved after IVB.9 Thus, DME exhibits
a variety of treatment responses to different
pharmacologic agents, such that it would be
beneficial to determine, based on OCT find-
ings, which type of DMEmight demonstrate
the most favorable response to each treat-
ment (e.g., anti-VEGF or corticosteroid).
This knowledge would support clinicians in
making informed decisions for DME treat-
ment. Thus, we hypothesized that clear dis-
cernment of patterns of DME, based on
spectral-domain OCT (SD-OCT), may be
useful for the prediction of anatomical
outcomes following treatment with either
anti-VEGF agents or corticosteroids. The
aim of this study was to determine whether
pretreatment morphology of DME was
significantly correlated with response to dif-
ferent treatments, as determined by analysis
of changes in the morphology of DME on




This retrospective study enrolled patients
with type 2 diabetes mellitus who were ini-
tially treated with either 1.25 mg of IVB or
40 mg of posterior sub-tenon triamcinolone
injection (PSTI) for the treatment of DME,
from December 2007 to December 2012.
Patients were not randomized to IVB or
PSTI at the time. Patients had received
PSTI for DME between 2007 and 2008
when IVB was not available at our institute.
Those who visited our clinic after 2008
received IVB as their initial treatment for
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DME. Inclusion criteria for this study were
the following: 1) central macular thickness
(CMT) of >300 mm; 2) presence of cystoid
macular edema, with or without serous ret-
inal detachment, within an area of 1 mm
centered on the fovea; 3) absence of any
mechanical traction exerted on the fovea;
4) absence of other retinal or choroidal
pathologies; and 5) OCT images of suffi-
cient quality to discern retinal morphologi-
cal changes. Exclusion criteria included: 1)
previous vitrectomy; 2) panretinal photoco-
agulation, IVB, PSTI, or cataract surgery
within 6 months; 3) focal laser treatment
within 1 year; 4) other ocular diseases; and
5) serum creatinine >3 mg/dL. In all eyes,
CMT measurement by SD-OCT and a com-
plete ophthalmic examination (including
slit lamp biomicroscopic examination,
fundus examination, and intraocular
pressure measurements) were performed
preoperatively and at 1 month postopera-
tively. Additionally, prior to treatment,
fluorescein angiography was performed
with a confocal scanning laser ophthalmo-
scope (HRA 2; Heidelberg Engineering,
Heidelberg, Germany) after intravenous
injection with 5 mL of 20% sodium fluores-
cein, excluding patients with evidence of
macular ischemia.
To determine the effects of IVB and
PSTI on DME, with respect to SD-OCT
patterns, eyes with DME were divided
into two groups based on the presence or
absence of SRD under the macula within
500 mm from the fovea, as determined by
SD-OCT findings. In each group, eyes
were further divided into two subgroups
on the basis of treatments with either IVB
or PSTI; SD-OCT findings were analyzed
both quantitatively and qualitatively at
1 month postoperatively to determine
short-term anatomical responses to treat-
ments. This study was approved by the
Institutional Review Board of Yonsei
University College of Medicine (IRB
approval: 3-2013-0314), and was conducted
in accordance with the tenets of the
Declaration of Helsinki. Informed consent
was obtained from all patients.
Optical coherence tomography
image assessment
SD-OCT (Cirrus HD-OCT, Carl Zeiss
Meditec, Dublin, CA, USA) was performed
and CMT was defined as the distance from
the retinal pigment epithelium (RPE) to the
internal limiting membrane (ILM). CMT
was measured on a 1-mm circle, centered
on the fovea, by using the mapping proto-
col of the OCT software (Figure 1a). SRD
was defined as the presence of subretinal
fluid between the neurosensory retina and
the RPE, and was measured as the greatest
distance from the RPE to the external lim-
iting membrane (ELM), within 500 mm of
the fovea, by using digital calipers within
the Cirrus OCT software (Figure 1b).
Intraretinal edema was defined as the dis-
tance from the ELM to ILM, and was cal-
culated as [CMT – SRD]. The proportion
of improvement in CMT was assessed by
the reduction ratio, which was calculated
as [(CMT at baseline – CMT at 1 month
post injection)/CMT at baseline 100
(%)]. Independent measurements were per-
formed twice by two different blinded
examiners, and the average value was used
for calculations.
Intervention
All patients were placed in the supine posi-
tion; after topical 0.5% proparacaine
hydrochloride and 5% povidone-iodine
application, an eyelid speculum was used
to stabilize the eyelids. After treatment, a
small volume of topical 0.5% moxifloxacin
eyedrops was instilled. For IVB, the injec-
tion of 1.25 mg (0.05 mL) bevacizumab
(Avastin; Genentech, Inc., San Francisco,
CA, USA) was performed at 3.5 to 4 mm
posterior to the limbus, through the pars
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plana, with a 30-gauge needle. For PSTI, a
small incision (8 mm posterior to the
limbus) was made through the conjunctiva
and Tenon’s capsule, to bare sclera, by
using Westcott tenotomy scissors. The
curved portion of the cannula was inserted,
and the study medication was slowly
injected behind the eye. One milliliter of a
40 mg/mL triamcinolone acetonide solution
(Hanall Biopharma, Seoul, Korea) was
delivered through the inferotemporal or
superotemporal fornix, by using a curved
cannula. When the depot application was
complete, the cannula was withdrawn
slowly, with gentle pressure maintained by
a sterile swab, along the path of the cannu-
la. No drug reflux was observed.
Statistical analysis
For descriptive purposes, quantitative data
are reported as mean standard deviation.
For comparison of baseline characteristics,
Pearson’s chi-squared test or Fisher’s exact
test were used for qualitative data and the
Mann-Whitney U test was used for quantita-
tive data. For comparison of CMT, intrareti-
nal edema, and SRD between the groups, the
Mann-Whitney U test was used and for com-
parison within the same group, the Wilcoxon
signed rank test was used. P values less than
0.05 were considered statistically significant.
Statistical analyses were performed using
PASW Statistics for Windows, Version 18.0
(SPSS Inc., Chicago, IL, USA).
Figure 1. (a) Central macular thickness (CMT) was measured on the 1-mm Early Treatment Diabetic
Retinopathy Study (ETDRS) circle (bold) centered on the fovea by using the mapping protocol of the OCT
software. (b) Measurement of serous retinal detachment (SRD) was defined as the greatest distance (H)
from the retinal pigment epithelium (RPE) to the external limiting membrane (ELM) within 500 mm of the
fovea, as determined by using digital calipers. Intraretinal edema was defined as the distance from the ELM to
the internal limiting membrane (ILM), and was calculated as [CMT – SRD].
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Results
Demographic data
A total of 73 eyes of 73 patients that satis-
fied the inclusion and exclusion criteria
were enrolled in the study. Thirty-two eyes
were classified into the SRD group and 41
eyes into the non-SRD group. There were
no statistically significant differences in age,
sex, severity of diabetic retinopathy, previ-
ous history of treatment, serum level of gly-
cohemoglobin, or creatinine levels. The
baseline characteristics of each group are
summarized in Table 1. There were only
six patients (three in each group) who had
received focal laser treatment at least 1 year
before IVB or PSTI; none of the patients
had received any injections, either intravi-
treally or via the sub-tenon route, for the
treatment of DME.
Morphological changes after treatment
of DME with SRD
The average preoperative CMT in eyes with
SRD did not significantly differ between
IVB and PSTI groups. At 1 month postop-
eratively, CMT was significantly reduced in
both groups (P¼ 0.001 for both). There was
no significant difference in total CMT
reduction between the two groups
(Table 2). With regard to changes in SRD,
both groups exhibited significant reductions
(P¼ 0.001 for both). Regarding changes in
intraretinal edema, the IVB group showed
mild but insignificant improvement,
whereas the PSTI group, showed significant
improvement (P¼ 0.002) (Figure 2;
Table 2).
Overall, in DME with SRD, the IVB and
PSTI groups achieved similar anatomical
improvement in terms of the reduction of
CMT. However, there was a greater
degree of SRD reduction in eyes treated
with IVB than in eyes treated with PSTI
(P¼ 0.001). The improvement of intrareti-
nal edema was greater in the PSTI group
than in the IVB group (P¼ 0.045) (Table 2).
Morphological changes after treatment
of DME without SRD
The average preoperative CMT in eyes
without SRD improved in both IVB and
PSTI groups (P¼ 0.038 and P¼ 0.001,
respectively) (Figure 3; Table 2). Overall,
in DME without SRD, PSTI was more
Table 1. Demographics and clinical characteristics of patients with diabetic macular edema.
SRD group (n¼32) No SRD group (n¼41)
IVB group PSTI group P value IVB group PSTI group P value
Eyes 19 13 22 19
Age (years) 52.6 14.0 59.0 13.4 0.305* 57.0 12.1 64.2 9.6 0.089*
Sex, Male/Female 10/9 5/8 0.491† 18/4 13/6 0.469†
NPDR/PDR 14/5 7/6 0.283† 13/9 12/7 0.790†
Previous focal laser 3 2 0.999‡ 6 4 0.727‡
Previous anti-VEGF injection 0 1 0.406‡ 0 3 0.091‡
Previous PSTI 2 2 0.999‡ 4 3 0.999‡
HbA1c (%) 8.9 2.5 8.6 0.9 0.860* 8.2 1.3 9.4 2.4 0.200*
Creatinine (mg/dL) 1.04 0.63 1.20 0.52 0.485* 1.36 1.88 1.27 1.07 0.067*
SRD¼ serous retinal detachment; IVB group¼ intravitreal bevacizumab group; PSTI group¼ posterior sub-tenon triam-
cinolone injection group; HbA1C¼ hemoglobin A1c; NPDR¼ nonproliferative diabetic retinopathy; PDR¼ proliferative
diabetic retinopathy; VEGF¼ vascular endothelial growth factor.
*Mann-Whitney U test; †Pearson’s chi-squared test; ‡Fisher’s exact test.
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effective in achieving greater CMT reduc-
tion than IVB (P¼ 0.01) by improvement
of intraretinal edema (Table 2).
Ocular/systemic complications
No patients developed any systemic compli-
cations, such as cerebrovascular accidents
associated with the use of intravitreal anti-
VEGF injections. No ocular complications,
including cataracts, increased intraocular
pressure, endophthalmitis, retinal detachment
or RPE tears, blepharoptosis, and proptosis,
were noted, with the exception of transient
chemosis and subconjunctival hemorrhage.
Table 2. Quantitative changes of OCT parameters in eyes with diabetic macular edema.
CMT (mm)
SRD group (n¼32) No SRD group (n¼41)
IVB group PSTI group P value* IVB group PSTI group P value*
Reduction of (mm)
CMT 136.53 100.75 136.23 96.89 0.773† 19.47 13.49 139.56 126.91 0.001†
Intraretinal edema 22.29 7.39 83.23 79.84 0.039† – – –
SRD 114.24 60.23 53.00 39.76 <0.01† – – –
% of improvement
CMT 28.80 18.96 28.10 15.83 0.805† 3.87 2.17 23.78 20.10 0.001†
Intraretinal edema 4.94 3.87 28.33 22.58 0.045† – – –
SRD 50.21 19.62 27.61 15.57 0.001† – – –
CMT¼ central macular thickness; IVB¼ intravitreal bevacizumab; PSTI¼ posterior sub-tenon triamcinolone injection;
SRD¼ serous retinal detachment, measured as perpendicular distance from RPE to ELM; intraretinal edema¼ [CMT –
SRD]; ELM¼ external limiting membrane; RPE¼ retinal pigment epithelium; % of improvement¼ [(thickness at baseline
minus thickness at 1 month postoperatively)/thickness at baseline 100 (%)].
*Comparison between IVB and PSTI groups; †Mann-Whitney U test.
Figure 2. Morphological changes of diabetic macular edema with serous retinal detachment, as measured
by SD-OCT. (a) One month after intravitreal bevacizumab treatment (IVB), macular edema, including all
subretinal and intraretinal components, was resolved, and subretinal fluid had subsided completely. (b) One
month after posterior sub-tenon triamcinolone injection (PSTI), macular edema had decreased slightly, but
subretinal fluid components persisted.
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Discussion
Despite major advances in the treatment of
DME, many aspects of the disease remain
unresolved. In particular, it would be highly
beneficial to identify factors that can pre-
dict which type of DME would most benefit
from a particular treatment. Our retrospec-
tive analysis of DME patients treated with
either IVB or PSTI showed that, in DME
with SRD, IVB resulted in greater reduc-
tion of subretinal fluid, compared with
PSTI; however, PSTI showed greater
improvement of intraretinal edema.
Notably, DME without SRD also showed
a greater improvement of retinal edema
when treated by PSTI than when treated
by IVB. This suggests that the classification
of DME, based on OCT findings, may have
important clinical implications for predict-
ing anatomical improvement of DME in
response to different pharmacologic agents.
The pathophysiology of DME is multi-
factorial and complex, and the precise caus-
ative mechanism for SRD has not been
clearly elucidated. Although anti-VEGF
treatment is effective in reducing the
degree of DME, VEGF is one of many
key factors involved in the pathogenesis of
DME, and many inflammatory cytokines
have been reported to contribute to the
development of DME.3,4 Past studies have
shown higher concentrations of VEGF, as
well as inflammatory cytokines, in patients
with DME.5 Moreover, recent studies
revealed significant correlations between
the OCT reflectivity of SRD and intravi-
treal VEGF concentration in eyes with
DME.10 Additionally, the concentration of
interleukin-6 (IL-6) was found to be signif-
icantly higher in eyes with SRD than in eyes
with CME or diffuse swelling; there was a
significant correlation between the levels of
VEGF and IL-6.11 These results collectively
imply that there may be different key mech-
anisms involved in the development of spe-
cific types of DME, based on OCT
classification; this may explain the varying
treatment responses to certain pharmaco-
logic agents.12
Our study showed that the reduction of
intraretinal edema was greater than the
Figure 3. Morphological changes of diabetic macular edema without serous retinal detachment, as
determined by SD-OCT. (a) At 1 month after intravitreal bevacizumab treatment (IVB), macular edema
persisted, along with its intraretinal components. (b) At 1 month after posterior sub-tenon triamcinolone
injection (PSTI), macular edema improved significantly, along with its intraretinal components.
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reduction of subretinal fluid in eyes receiv-
ing PSTI, compared with IVB; this implies
that PSTI may be more effective in DME
predominantly comprising fluid accumula-
tion within the retinal layers, such as CME
or diffuse swelling, but not in DME with
SRD. Several previous studies have shown
the effectiveness of either IVTA or IVB.
In a retrospective analysis of the effect of
IVTA in DME patients, Shimura et al.13
reported that IVTA was more effective in
patients with CME, while IVTA was less
effective in patients with SRD. Although
the pathogenesis of DME remains unclear,
CME is thought to be caused by intracyto-
plasmic swelling of Mu¨ller cells.14 Shimura
et al.13 suggested that triamcinolone may
reduce hypoxia-induced inhibition of fluid
absorption, which could stimulate the Naþ
transporter and Naþ/Kþ-ATPase to reduce
cytoplasmic swelling, similar to the mecha-
nism exhibited by pulmonary alveolar
cells.15 Further, the effect of triamcinolone
was reported to be protective against oxida-
tive stress-induced disruption of the RPE
tight junction.15 Thus, we hypothesize that
the resorption of fluid within the inner and
outer retinal layers may be more effectively
achieved by the action of triamcinolone
delivered by PSTI. In contrast, other studies
have shown that IVB is more effective for
sponge-like diffuse retinal thickening, but
less effective for SRD.16,17 Liu et al.16
reported that IVTA was superior to IVB
in treatment of DME combined with
SRD, but was inferior to IVB in treatment
of diffuse macular thickening. Unlike the
present study, the prospective study by
Liu et al.16 used IVTA in place of PSTI
for the treatment of DME; it further
differed in that the study population
comprised three different groups (DME
combined with SRD, diffuse macular thick-
ening, and CME). Additionally, the prior
study population did not receive any treat-
ment before either IVTA or IVB. Shimura
et al.17 revealed that the improvement of
foveal thickness and visual acuity after
IVB was greater in the group with sponge-
like diffuse retinal thickening than in the
SRD group; their prospective study focused
on the effect of IVB only in patients with
DME, such that a direct comparison
between IVTA and IVB was not possible.
The different outcomes of these studies may
be attributable to the significant differences
in baseline CMT among the different treat-
ment groups in each study.16 Furthermore,
their study results occasionally demonstrat-
ed complete resolution of SRD after a
single injection of IVB.17 Therefore,
because the pathogenesis of SRD remains
unclear, further studies are warranted to
elucidate the precise correlation between
morphological patterns of DME on OCT
and observed therapeutic responses.
Although intravitreal delivery of triam-
cinolone has shown therapeutic effects on
refractory DME,18 it has also been associat-
ed with complications such as cataract and
endophthalmitis.19,20 Notably, PSTI deliv-
ers a large amount of drug to the posterior
segment of the eye, via transscleral absorp-
tion,21,22 and has been widely used as treat-
ment for CME secondary to uveitis.23,24
Additionally, several studies have reported
significant reduction in CMT after PSTI in
DME patients.24,25 In our study, we used the
posterior sub-tenon route for safer delivery
of triamcinolone, in order to minimize com-
plications associated with the intravitreal
use of triamcinolone; no complications
were noted in the study.
Our study has several limitations,
namely a lack of randomization to either
IVB or PSTI treatments owing to the retro-
spective nature of the study, a relatively
small number of patients, and short dura-
tion. However, our study was intentionally
designed to analyze the short-term anatom-
ical response of DME based on pretreat-
ment morphological patterns of DME by
OCT. The 1-month follow-up period
seemed most appropriate to observe the
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immediate effects of a single pharmacologic
agent on DME, because longer follow-up
evaluations of eyes would have resulted in
a combination of different treatments
administered to the eyes after the initial
treatment with either IVB or PSTI.
Because this was only a 1-month follow-
up study, correlations between visual
acuity and OCT patterns were not evaluat-
ed. Furthermore, some patients had
received other treatments for DME before
the initiation of the study, which may have
affected the results of our study. To inves-
tigate this relationship further, a large pro-
spective randomized controlled trial
is warranted.
In conclusion, in patients with DME, the
degree of SRD reduction was greater in
eyes treated with IVB than in those treated
with PSTI; intraretinal edema showed a
more favorable response to PSTI than
IVB, regardless of the presence of SRD.
Our study indicated that morphological
classification of DME, based on OCT
results, might be useful to predict short-
term anatomical responses to different
treatments. Further OCT studies are war-
ranted to clarify the clinical relationships
between the pathophysiology and morpho-
logical features of DME.
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